Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.
The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.
The team demonstrated that the approach can yield high sensitivity while maintaining near-perfect specificity, but it must now replicate the early results in a much larger study.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
Researchers showed that the company's chips can be used to rapidly isolate exosomes from plasma or whole blood samples, allowing testing of cancer diagnostic markers.
The company hopes to replicate its early data in future studies, making a case that better early diagnosis can improve outcomes for patients with schizophrenia and bipolar disorder.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
The company is expecting that existing users from its technology access program are likely to purchase instruments when they become available later this year.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.